PubMed | Red Cross, Gpapanikolaou General Hospital Of Thessaloniki, National and Kapodistrian University of Athens, General Hospital of Kavala and 21 more.
Type: | Journal: Infectious diseases (London, England) | Year: 2015
To evaluate the in vitro efficacy of several anti-staphylococcal agents against a nationwide collection of contemporary Staphylococcus aureus clinical isolates from several healthcare centres in Greece.Thirty hospitals throughout Greece (18 in Attica) provided all clinical isolates of S.aureus from April 2012 to May 2013 to a central lab to be re-submitted to susceptibility testing. The MICs were evaluated by Vitek 2 with the exception of ceftaroline (OXOID M.I.C. Evaluator). Vancomycin and daptomycin MICs were also evaluated by Etest. Heterogeneously vancomycin-intermediate strains (hVISA) were detected by the Etest GRD. VISA phenotype was confirmed by PAP-AUC.A total of 1005 isolates (39% MRSA) were studied. Susceptibility rates were: erythromycin 66.5%, clindamycin 79.2%, SXT 98.9%, rifampicin 97.3%, fusidic acid 67%, moxifloxacin 78.8%, vancomycin 99.9%, ceftaroline 92.9% and linezolid, tigecycline and daptomycin 100%. For mupirocin, high level resistance could be excluded for 98.9% of isolates. Vancomycin Etest MICThis multi-centre surveillance study revealed that a significant percentage of contemporary S.aureus isolates from Greek patients have a vancomycin MIC (>1mg/L) that may compromise the clinical efficacy of the drug for the treatment of serious infections. The in vitro activity of SXT, rifampicin, mupirocin, linezolid, tigecycline, daptomycin and ceftaroline remains excellent.